76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
LivaNova PLC
Closed
45.82 -0.02
Overview
Share price change
24h
Min
45.42
Max
45.95
Income | -383M -327M |
|---|---|
Sales | -4.9M 317M |
P/E Sector Avg | 31.716 50.291 |
EPS | 0.88 |
Profit margin | -103.303 |
Employees | 2,900 |
EBITDA | -371M -286M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +39.34% upside |
Next Earnings | 30 Jul 2025 |
|---|
Market Cap | 479M 2.5B |
|---|---|
Previous open | 45.84 |
Previous close | 45.82 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
LivaNova PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
LivaNova PLC Forecast
Price Target
By TipRanks
39.34% upside
12 Months Forecast
Average 64.14 USD 39.34%
High 79 USD
Low 55 USD
Based on 7 Wall Street analysts offering 12 month price targets forLivaNova PLC - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
